8-KMaterial Agreements

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (May 6, 2010)

Filed May 6, 2010For Securities:GILD

Summary

Gilead Sciences, Inc. (GILD) has filed an 8-K report detailing an amendment to a material definitive agreement. Specifically, on April 30, 2010, Gilead Sciences Limited, a subsidiary, amended its Emtricitabine Manufacturing Supply Agreement with Evonik Degussa GmbH. This amendment is significant as emtricitabine is a key component in several of Gilead's important HIV medications, including Emtriva®, Truvada®, and Atripla®. The amendment primarily extends the supply agreement's term by one year, to December 31, 2014. Importantly, it also includes favorable terms for Gilead, such as a reduction in the purchase price and a decrease in minimum payment obligations. Additionally, the amendment establishes a process for handling raw material price fluctuations, offering greater predictability and potential cost control for Gilead. Investors should view this as a positive development, ensuring continued supply of a critical active pharmaceutical ingredient while potentially improving cost efficiencies.

Key Highlights

  • 1Gilead Sciences amended its Emtricitabine Manufacturing Supply Agreement with Evonik Degussa GmbH.
  • 2Emtricitabine is a key active pharmaceutical ingredient for Gilead's HIV drugs Emtriva®, Truvada®, and Atripla®.
  • 3The supply agreement term has been extended by one year, from December 31, 2013, to December 31, 2014.
  • 4The amendment includes a reduction in the purchase price of emtricitabine.
  • 5Minimum payment obligations under the supply agreement have been reduced.
  • 6A procedure for managing raw material price fluctuations related to emtricitabine production has been established.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce an amendment to a material definitive agreement, specifically the Emtricitabine Manufacturing Supply Agreement between Gilead Sciences Limited and Evonik Degussa GmbH.

Emtricitabine is a crucial active pharmaceutical ingredient for Gilead's significant HIV treatment drugs, including Emtriva®, Truvada®, and Atripla®. Ensuring a reliable and cost-effective supply of this ingredient is vital for the company's revenue and market position in HIV therapeutics.

The amendment extends the supply agreement for one year to December 31, 2014, reduces the purchase price of emtricitabine, lowers minimum payment obligations for Gilead, and establishes a new process for handling raw material price fluctuations.

While the filing itself doesn't provide specific financial figures, the reduction in purchase price and minimum payment obligations, along with the management of raw material price volatility, suggests potential for improved cost efficiency and profitability for Gilead related to the production of emtricitabine.